Lymphoma: Clinical Trials

166 trials for Lymphoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

44 unknown, 34 recruiting, 30 completed, 19 terminated. 166 Early Phase 1.

By phase and status

PhaseTrialsStatus
Early Phase 1166Unknown 44, Recruiting 34, Completed 30, Terminated 19, Not yet recruiting 18, Active not recruiting 11, Withdrawn 6, Suspended 4

Follow Lymphoma: new trials by email Literature Review of Lymphoma trials Research Report on Lymphoma

Trials (filtered) newest first · largest first

All 166 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution
APR-TD011 (RLF-TD011) - Cutaneous T Cell Lymphoma
Early Phase 1Not yet recruitingNorthwestern University302027-01-012026-05-01
SNC116 Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
SNC116 - B-cell Acute Lymphoblastic Leukemia
Early Phase 1Not yet recruitingShanghai Simnova Biotechnology Co.,Ltd.282026-09-012026-09-21
GoFast CAR T-Cell Therapy for Recurrent Refractory B-Cell Lymphoma
GoFast CD19 CAR T Cells - Relapsed or Refractory Large B-cell Lymphoma
Early Phase 1Not yet recruitingChinese PLA General Hospital92026-06-302026-06-26
A Clinical Study of Humanized CD19 CAR-T Cells With TLR2 for the Treatment of Adult Patients With Naive B-Cell Acute Lymphoblastic Leukemia/Lymphoma Who Are Intolerant to Intensive Chemotherapy
humanized CD19 CAR-T Cells with TLR2 - B Lymphoblastic Leukemia/Lymphoma
Early Phase 1Not yet recruitingZhujiang Hospital602026-06-012026-01-12
A Single Dose, Dose Escalation Clinical Trial on the Safety, Tolerability and Efficacy of Lyophilized Powder for Inhalation of Recombinant Human Keratinocyte Growth Factor-2 (Rh-KGF-2) in The Treatment of Patients With Acute Respiratory Distress Syndrome
Recombinant Human Keratinocyte Growth Factor-2 for Inhalation (Lyophilized Powder) - ARDS (Moderate or Severe), ARDS (Acute Respiratory Distress Syndrome)
Early Phase 1RecruitingShanghai Zhongshan Hospital242026-05-142026-06-11
RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas
RN1701 injection - Relapsed/Refractory B-cell Lymphoma
Early Phase 1Not yet recruitingThe First Affiliated Hospital with Nanjing Medical University102026-05-082026-05-04
Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors
Methionine-Reduced Diet - Adenocarcinoma, Basal Cell Carcinoma
Early Phase 1RecruitingUniversity of California, Irvine252026-05-012026-07-31
Exploratory Study on the Treatment of EB Virus Positive HIV Associated Lymphoma With EBV mRNA Vaccine
EBV mRNA vaccine - HIV Associated Lymphoma
Early Phase 1Not yet recruitingWest China Hospital62026-05-012026-05-01
Nanobody-Based CD19/CD20 Tandem Dual CAR-T-cell Therapy of Relapsed/Refractory B-Cell Lymphoma
CD19/CD20 Tandem Dual CAR-T - Relapsed/Refractory B-Cell Lymphoma
Early Phase 1Not yet recruitingAffiliated Hospital to Academy of Military Medical Sciences202026-04-302026-04-29
A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma
CT1182 injection - B-cell Non Hodgkin Lymphoma (NHL), DLBCL - Diffuse Large B Cell Lymphoma
Early Phase 1RecruitingUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology242026-04-302026-04-23
Evaluation of GI001 for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
GI001 Injection - B-Cell Non-Hodgkin Lymphoma
Early Phase 1Not yet recruitingRuijin Hospital92026-04-202026-05-13
CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation
CAR19BCMA-T cells, fludarabine and cyclophosphamide - Relapsed or Refractory Plasma Cell Neoplasms, Lymphomas/Leukemias With Plasmacytic Differentiation
Early Phase 1Not yet recruitingAffiliated Hospital to Academy of Military Medical Sciences202026-04-022026-04-08
CD30 CAR-T in the Treatment of CD30 Positive Lymphoma
chimeric antigen receptor gene modified T cells - Lymphoma, B Cell Lymphoma
Early Phase 1SuspendedShandong Qilu Cell Therapy Engineering Technology Co., Ltd152026-03-012026-09-28
Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia
SYNCAR-100 Injection - B-Cell Acute Lymphoblastic Leukemia
Early Phase 1RecruitingZhejiang University162026-02-282026-02-24
A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)
DT-7012 - Cutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides
Early Phase 1Not yet recruitingAssistance Publique - Hôpitaux de Paris302026-01-012025-10-09
Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma
Conditioning chemotherapy followed by AbTCR (anti-CD19/CD22)-T cell infusion - Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma ( FL)
Early Phase 1Not yet recruitingFirst Affiliated Hospital Xi'an Jiaotong University32025-12-312025-09-17
A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
IMV101 treatment - Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Early Phase 1RecruitingSuzhou Immunofoco Biotechnology Co., Ltd302025-12-292026-03-30
Allogeneic UCB-derived CAR-T for B-ALL
allogeneic umbilical cord blood-derived CAR-T - B-Cell Acute Lymphoblastic Leukemia, Adult
Early Phase 1Not yet recruitingThe General Hospital of Western Theater Command502025-12-012025-12-01
Autologous Bedside CD19 CAR T-cell Therapy for B-ALL
CD19 CAR T cells - B-Cell Acute Lymphoblastic Leukemia, Adult
Early Phase 1Not yet recruitingThe General Hospital of Western Theater Command502025-12-012025-12-11
Study of GI001 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia
GI001 - B-Cell Non-Hodgkin Lymphoma, B-Cell Acute Lymphoblastic Leukemia
Early Phase 1RecruitingHematology department of the 920th hospital182025-11-282026-10-07

Showing 20 of 166. Sign in to see all of them.

Narrower conditions

Lymphoma, B-Cell (37)  ·  Lymphoma, Non-Hodgkin (37)  ·  Burkitt Lymphoma (29)  ·  Lymphoma, Large B-Cell, Diffuse (21)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (21)  ·  Lymphoma, Follicular (19)  ·  Lymphoma, Mantle-Cell (15)  ·  Recurrence (13)  ·  Hodgkin Disease (12)  ·  Multiple Myeloma (12)  ·  Leukemia (11)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (11)  ·  Lymphoma, T-Cell (9)  ·  Lymphoma, T-Cell, Peripheral (8)

Broader conditions

Hemic and Lymphatic Diseases (166)  ·  Immune System Diseases (166)  ·  Immunoproliferative Disorders (166)  ·  Lymphatic Diseases (166)  ·  Neoplasms by Histologic Type (166)  ·  Lymphoproliferative Disorders (165)  ·  Neoplasms (161)  ·  Lymphoma, Non-Hodgkin (96)  ·  Hematologic Diseases (51)  ·  Lymphoma, B-Cell (43)  ·  Leukemia (34)  ·  Leukemia, Lymphoid (32)  ·  DNA Virus Infections (31)  ·  Herpesviridae Infections (31)

Interventions

Cyclophosphamide (18)  ·  Rituximab (10)  ·  fludarabine (9)  ·  Doxorubicin (5)  ·  Etoposide (5)  ·  Vincristine (5)  ·  Immunotherapy, Adoptive (4)  ·  Methotrexate (4)  ·  Prednisone (4)  ·  Radiotherapy (4)  ·  pembrolizumab (4)  ·  68Ga-pentixafor (3)  ·  Dexamethasone (3)  ·  Filgrastim (3)  ·  Granulocyte Colony-Stimulating Factor (3)

Sponsors

Zhejiang University (10)  ·  He Huang (5)  ·  M.D. Anderson Cancer Center (5)  ·  Memorial Sloan Kettering Cancer Center (5)  ·  Northwestern University (5)  ·  Allife Medical Science and Technology Co., Ltd. (4)  ·  Anhui Provincial Hospital (4)  ·  Hebei Yanda Ludaopei Hospital (4)  ·  Mayo Clinic (4)  ·  920th Hospital of Joint Logistics Support Force of People's Liberation Army of China (3)  ·  Institute of Hematology & Blood Diseases Hospital, China (3)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3)  ·  Timmune Biotech Inc. (3)  ·  Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (3)  ·  University of Kansas Medical Center (3)

Countries

China (78)  ·  United States (64)  ·  Australia (2)  ·  Canada (1)  ·  Czechia (1)  ·  Indonesia (1)  ·  Spain (1)  ·  Sweden (1)

Top investigators

Ariela Noy, MD (2)  ·  Fang Liu, MD, PhD (2)  ·  Farrokh Dehdashti, M.D. (2)  ·  Hai Yi, M.D. & Ph.D. (2)  ·  Hongyu Zhang, MD, PhD (2)  ·  Jeffrey J. Raizer, MD (2)  ·  Qingming Wang, M.D. (2)  ·  Sunil Abhyankar, MD (2)  ·  Xi Zhang, MD (2)  ·  Yi Yao, ph.D (2)  ·  Aaron Mangold (1)  ·  Alan Zhou (1)  ·  Ali Dana, MD (1)  ·  Andrew M. Evens, DO, MS (1)

Results publications

PMID 40540129, PMID 18042692, PMID 19880495, PMID 20671118, PMID 23023715, PMID 23649469, PMID 24142051, PMID 26202875, PMID 26222726, PMID 26353084, PMID 26424652, PMID 27269947, PMID 28911074, PMID 29652233, PMID 29920566, PMID 29925499, PMID 31776631, PMID 32840736, PMID 33242451, PMID 33851477, PMID 34344873, PMID 34435552, PMID 34651291, PMID 35468680, PMID 35973200, PMID 36189306, PMID 36719647, PMID 36808074, PMID 36923556, PMID 37077913, PMID 37093350, PMID 37192741, PMID 37781191, PMID 38143760, PMID 38592213, PMID 39563035, PMID 40311885, PMID 40406106, PMID 40574863, PMID 40940923, PMID 41110448, PMID 41194247, PMID 41538301, PMID 41633358, PMID 41776652, PMID 42255257, PMID 42490071, PMID 42845554

NIH funding

P30CA043703 (2), K12CA090433 (1), P30CA006973 (1), P30CA015083 (1), P30CA033572 (1), P30CA036727 (1), P30CA060553 (1), P30CA072720 (1), P30CA138292 (1), P50CA097274 (1), R01CA277493 (1), R42CA257797 (1), UM1CA121947 (1)